Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally

On May 15, 2026, Paradigm Biocapital Advisors disclosed in an SEC filing that it sold 3,766,393 shares of Erasca (NASDAQ:ERAS) in the first quarter, an estimated $44.52 million transaction based on quarterly average pricing.According to a May 15, 2026, SEC filing, Paradigm Biocapital Advisors reduced its holding in Erasca by 3,766,393 shares during the first quarter of 2026. The estimated value of the shares sold was $44.52 million, calculated using the mean unadjusted closing price for the quarter. The quarter-end value of the position, after accounting for price appreciation, was $168.15 million.Erasca is a clinical-stage biotechnology company specializing in the development of therapies for RAS/MAPK pathway-driven cancers. The company's strategy centers on advancing a pipeline of novel, targeted oncology candidates addressing significant unmet needs in solid tumors and hematologic malignancies. With a focus on innovation in precision medicine, Erasca aims to establish a competitive edge through differentiated drug mechanisms and a robust clinical development program.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool